Receptos
Inc. introduced that in fact company team members is going to deliver a
scientific podium presentation about RPC1063 near the Digestive Disease Week
(DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 along at the San
Diego Convention Center in San Diego, California. DDW interests a large number
of physicians, scientists, and academics from worldwide to share the most
contemporary research in gastrointestinal health matters, for which actually
DDW is the premier scientific meeting. Based on an abstract entitled "A
small particle S1P1 receptor agonist with major efficacy in animal types of
inflammatory bowel disease (IBD)," Receptos scientific team members will
talk about positive preclinical data with RPC1063 in two distinct in vivo types
of IBD.
"Based
on exciting statistics from each of these preclinical studies, in addition to
data from a recently completed Phase 1 clinical safety learn, Receptos will
initiate a Phase 2 clinical trial along with RPC1063 in 2012 in inflammatory
bowel disorder," said Faheem Hasnain, President and Chief Executive
Officer of Receptos. "The approval of these preclinical efficacy data for
preview at DDW underscores the necessity of efficacious oral treatments for
therapeutic treatment of IBD and the exhilaration on behalf of scientific and
medical professionals to review the novel profile of RPC1063 in affected
individuals suffering from this devastating disorder."
No comments:
Post a Comment